10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.875.1999



Anti-LIMK1/2 (pT508/505) Antibody

Rabbit polyclonal antibody to LIMK1/2 (pT508/505) Catalog # AP59607

Product Information

Application WB, IF/IC, IHC

Primary Accession P53667

Reactivity Human, Rat, Chicken, Bovine

HostRabbitClonalityPolyclonalCalculated MW72585

Additional Information

Gene ID 3984

Other Names LIMK; LIM domain kinase 1; LIMK-1

Target/Specificity Recognizes endogenous levels of LIMK1/2 (pT508/505) protein.

Dilution WB~~WB (1/500 - 1/1000), IHC (1/100 - 1/200), IF/IC (1/100 - 1/500)

IF/IC~~N/A IHC~~WB (1/500 - 1/1000), IHC (1/100 - 1/200), IF/IC (1/100 -

1/500)

Format Liquid in 0.42% Potassium phosphate, 0.87% Sodium chloride, pH 7.3, 30%

glycerol, and 0.09% (W/V) sodium azide.

Storage Store at -20 °C.Stable for 12 months from date of receipt

Protein Information

Name LIMK1

Synonyms LIMK

Function Serine/threonine-protein kinase that plays an essential role in the regulation

of actin filament dynamics. Acts downstream of several Rho family GTPase signal transduction pathways (PubMed:10436159, PubMed:11832213,

PubMed: 12807904, PubMed: 15660133, PubMed: 16230460,

PubMed:<u>18028908</u>, PubMed:<u>22328514</u>, PubMed:<u>23633677</u>). Activated by upstream kinases including ROCK1, PAK1 and PAK4, which phosphorylate

LIMK1 on a threonine residue located in its activation loop

(PubMed:10436159). LIMK1 subsequently phosphorylates and inactivates the actin binding/depolymerizing factors cofilin-1/CFL1, cofilin-2/CFL2 and destrin/DSTN, thereby preventing the cleavage of filamentous actin (F-actin), and stabilizing the actin cytoskeleton (PubMed:11832213, PubMed:15660133, PubMed:16230460, PubMed:23633677). In this way LIMK1 regulates several

actin-dependent biological processes including cell motility, cell cycle progression, and differentiation (PubMed:11832213, PubMed:15660133, PubMed:16230460, PubMed:23633677). Phosphorylates TPPP on serine residues, thereby promoting microtubule disassembly (PubMed:18028908). Stimulates axonal outgrowth and may be involved in brain development (PubMed:18028908).

Cellular Location

Cytoplasm. Nucleus. Cytoplasm, cytoskeleton. Cell projection, lamellipodium {ECO:0000250|UniProtKB:P53668} Note=Predominantly found in the cytoplasm. Localizes in the lamellipodium in a CDC42BPA, CDC42BPB and FAM89B/LRAP25-dependent manner. {ECO:0000250|UniProtKB:P53668}


Tissue Location

Highest expression in both adult and fetal nervous system. Detected ubiquitously throughout the different regions of adult brain, with highest levels in the cerebral cortex. Expressed to a lesser extent in heart and skeletal muscle


Background

KLH-conjugated synthetic peptide encompassing a sequence within the C-term region of human LIMK1/2. The exact sequence is proprietary.

Images




Western blot analysis of LIMK1/2 (pT508/505) expression in rat brain (A), HEK293T-PMA-15min (B), HEK293T-PMA-5min (C), HEK293T (D) whole cell lysates.



Immunohistochemical analysis of LIMK1/2 (pT508/505) staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.

Immunofluorescent analysis of LIMK1/2 (pT508/505) staining in PC12 cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 °C in a humidified chamber. Cells were washed with PBST and incubated with a DyLight 594-conjugated secondary

antibody (red) in PBS at room temperature in the dark.



Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.